|
Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib. |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Novartis; Pfizer |
|
|
Honoraria - Bristol-Myers Squibb; Incyte; Novartis |
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Novartis |
Research Funding - Novartis |
Expert Testimony - Incyte; Novartis |
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Celgene; Incyte; Novartis |
|
|
Honoraria - Bristol-Myers Squibb; IL-Yang Pharm; Novartis |
Consulting or Advisory Role - Bristol-Myers Squibb; IL-Yang Pharm; Novartis; Pfizer |
Speakers' Bureau - Bristol-Myers Squibb; IL-Yang Pharm; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb; IL-Yang Pharm; Novartis; Pfizer; Takeda |
|
|
Consulting or Advisory Role - Amphivena Therapeutics; Astellas Pharma; Bio-Path Holdings, Inc; BiolineRx; Bristol-Myers Squibb; Daiichi Sankyo; Novartis; Pfizer; Takeda |
Research Funding - Ambit BioSciences (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Immunogen (Inst); Novartis (Inst); Pfizer (Inst); Sun Pharma (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - Ariad (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst) |
Research Funding - Ariad (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst) |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis |
|
|
Honoraria - Bayer; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Janssen; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Sanofi; Shire; Taiho Pharmaceutical; Takeda |
Consulting or Advisory Role - Merck Serono; Ono Pharmaceutical |
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst) |
|
|
Speakers' Bureau - Bristol-Myers Squibb; Novartis |
|
|
Consulting or Advisory Role - Amgen; Novartis |
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo; Novartis; Pfizer; Takeda |
Research Funding - Kyowa Hakko Kirin; Novartis; Ono Pharmaceutical |
|
|
Consulting or Advisory Role - Amgen; ARIAD; Bristol-Myers Squibb; Celgene; Immunogen; Incyte; Novartis; Pfizer; Shire |
|
|
Honoraria - Bristol-Myers Squibb; Incyte; Novartis; Pfizer |
|
|
Consulting or Advisory Role - CTI BioPharma Corp; Gilead Sciences; Nynex Therapeutics |
Research Funding - Aptose Biosciences; ARIAD; CTI BioPharma Corp; Gilead Sciences; Incyte; Novartis; Pfizer; Sanofi |
Expert Testimony - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Celgene; Incyte; Novartis; Pfizer; Sun Pharma; Sunesis Pharmaceuticals; Takeda |
Research Funding - Celgene; Incyte |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
Honoraria - Bristol-Myers Squibb; Incyte; Novartis; Pfizer |
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis |